Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | NAT1 | P18440 | 2/20 | 0.56 |
| ▸ | MYC | P01106 | 2/20 | 0.55 |
| ▸ | MAX | P61244 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962481 | 1.00 | CISD1 (0.68) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL6784135 | 0.84 | CISD1 (0.67) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL6784131 | 0.84 | CISD1 (0.67) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL22971854 | 0.81 | CISD1 (1.00) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL6789312 | 0.81 | ALDH1A1 (0.66) | ALDH1A1KMT2ATDP1KDM4EMEN1 | |
| SCHEMBL6789314 | 0.81 | ALDH1A1 (0.66) | ALDH1A1KMT2ATDP1KDM4EMEN1 | |
| SCHEMBL6785097 | 0.80 | SOS1 (0.63) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL6785099 | 0.80 | SOS1 (0.63) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL15863544 | 0.79 | AKR1B1 (0.65) | CISD1MAOBALDH1A1KMT2ATDP1 | |
| SCHEMBL15869614 | 0.79 | AKR1B1 (0.65) | CISD1MAOBALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727267-B2 | COMPOUND FOR USE IN THE TREATMENT OF VIRAL DISEASES | TULARIK INC. | 2004-04-27 | — | — | US | disclosed |
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | TULARIK INC. (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001077091-A2 | NS5B HCV POLYMERASE INHIBITORS | TULARIK INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | POLRMT, RNASE1, POLI | CISD1 3931/4885MAOB 607/4885ALDH1A1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.